Quarterly ResultApr 28, 2026, 06:12 AM
NAUT Q1 Net Loss $14.7M; Operating Expenses Down 14%
AI Summary
Nautilus Biotechnology, Inc. reported a net loss of $14.7 million for the first quarter of 2026, an improvement from a $16.6 million net loss in the prior year period. Operating expenses decreased by 14% to $16.1 million. The company also highlighted progress towards commercialization, including the initiation of its Iterative Mapping Early Access Program and the appointment of a new Vice President of Global Sales.
Key Highlights
- Q1 2026 net loss was $14.7 million, compared to $16.6 million in Q1 2025.
- Operating expenses decreased 14% to $16.1 million in Q1 2026 from $18.8 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026.
- Initiated Iterative Mapping Early Access Program with Baylor College of Medicine as first customer.
- Appointed Amber Faust as Vice President of Global Sales to lead customer expansion.
- Advanced development of a next-generation assay format to improve platform performance.